Background: TPI 1020 is a novel compound with potential for anti-neutrophil effects. TPI 1020 exerts its effects by a dual mechanism of action involving corticosteroid activity and controlled donation of nitric oxide. Objectives: We assessed the safety, pharmacodynamic and pharmacokinetic activity of ascending doses of TPI 1020 compared to budesonide in asthma.
Methods: Smokers with mild asthma (n Z 27) were randomized to receive either 600 mcg of TPI 1020 (n Z 13) or 400 mcg of budesonide (n Z 14) bid for 2 weeks followed by 1200 and 800 mcg bid, respectively, for an additional week. Result: There was no serious adverse event and all but one adverse event were mild or moderate (severe headache with budesonide). Patients receiving TPI 1020 reported three-fold fewer treatment-emergent AEs (n Z 13) than those receiving budesonide (n Z 39). TPI 1020 had similar effects as budesonide on FEV 1 , PEF, rescue medication, asthma scoring system, methacholine response, sputum eosinophils and exhaled NO. Sputum neutrophils (%) tended to decrease more with TPI 1020 (32.6% decrease versus 3.7% increase for budesonide); the decrease occurring only in patients with high neutrophils at baseline. A significant difference favoring TPI 1020 was noted for CRP. Budesonide caused a statistically significant decrease in 24 h urinary free cortisol over 22 days (median of 4.4e2.8 mcg/ml, p Z 0.01) whereas TPI 1020 had no such effect (4.4e5.8 mcg/ml), suggesting lower systemic corticosteroid exposure following TPI 1020 treatment. Conclusion: TPI 1020 appears safe in asthmatic smokers and warrants further investigation in respiratory conditions. ª 2009 Elsevier Ltd. All rights reserved.
Introduction
Bronchial asthma is widely recognized as a complex chronic inflammatory disorder of the airways characterized by acute episodes of airway obstruction, increased airways responsiveness and occasionally reduced pulmonary function. 1 In this disease exhaled nitric oxide (eNO) is increased when compared to normal individuals and eNO decreases when asthma improves. 2, 3 A discrepancy exists between the association of a decrease in eNO when asthma improves and the potential benefits of NO on inflammation and bronchoconstriction. Indeed, inhaled NO may be beneficial by reducing inflammatory cell adhesion and infiltration into the airways 4 as well as by promoting bronchodilation. 5 Högman et al. 6 demonstrated improved specific airway conductance after the inhalation of 80 parts per million (ppm) of NO in non-smoking subjects with hyperreactive airways and in individuals with a clinical diagnosis of asthma who were being maintained on short-acting b2 agonists and inhaled corticosteroids. Whether administering NO to patients with asthma that are receiving inhaled corticosteroids over a longer period of time is beneficial has not been studied.
TPI 1020 is a novel anti-inflammatory compound that is enzymatically cleaved in vivo to yield an NO donor and budesonide, most likely by esterases in the lung. 7 Nonclinical pharmacological studies have provided evidence that TPI 1020 may be effective in treating chronic obstructive pulmonary disease (COPD) and other respiratory diseases in humans where neutrophils are involved in the pathophysiology of the disease. 8 Interestingly, neutrophils seem to play a role in various phenotypes of asthma and have been shown to be increased in the sputum of smokers with asthma. 9 The objectives of this study was to determine the safety, pharmacodynamic (PD) and pharmacokinetic (PK) activity of multiple doses of inhaled TPI 1020 compared to that of equimolar doses of inhaled budesonide in subjects with mild asthma who smoke. We chose patients with asthma who smoke since these patients were reported to have not only an increase in neutrophils within their sputum, 9 as described in COPD but also a reduced response to inhaled corticosteroids.
Methods

Subjects and study design
This was a randomized (1:1), multi-center double-blind escalated-dose study. Individuals between 18 and 65 years old with stable, mild asthma by American Thoracic Society (ATS) criteria, 10 with a smoking history of 5e25 pack/years and continuing to smoke despite medical advice were eligible for enrolment. Subjects had not taken inhaled corticosteroids for at least 1 month. Forced expiratory flow in 1 s (FEV 1 ) must have been !75% of predicted value at least 4 h following use of rescue medication salbutamol and show significant reversibility (!12% and at least 200 mL after inhalation of salbutamol 200e400 mg during screening or within the last 6 months) or a positive methacholine challenge test as shown by a provocative concentration of methacholine (PC 20 ) 16 mg/mL within the last 5 years or a spontaneous fluctuation of FEV 1 !20% within the last 5 years.
Subjects who met the inclusion/exclusion criteria entered a 14-day run-in period with only a b-agonist bronchodilator (inhaled salbutamol) to use as needed. Subjects entered the therapeutic part of the study if they had a total symptom assessment score !2 and <6 on at least 3 days of the last 7 days of the run-in period or a peak expiratory flow (PEF) diurnal variation >15% and <30% on at least 3 days of the last 7 days of the run-in period in addition to a urine cotinine level !200 ng/mL at the screening visit, indicative of active smoking.
Those subjects who completed the 14-day run-in period were assigned to receive either inhaled TPI 1020 or budesonide over a 21-day period. Since TPI 1020 is 1.4 times heavier than budesonide on a 'budesonide' molar basis, the doses administered were as follows: budesonide 400 mg bid for 14 days then 800 mg bid for 7 days; TPI 1020: 600 mg bid for 14 days then 1200 mg bid for 7 days. Study treatments were delivered in lactose-based blends using the capsule-based Aeroliser dry powder inhaler. Budesonide capsules (Miflonide â , Novartis Pharmaceuticals) delivered 383 mg as compared to 423 mg of budesonide for TPI 1020 (equivalent to 9.5% more budesonide delivered to the body in the TPI 1020 group). However, the fine particle dose (<5 microns) of budesonide was 104 mg for the budesonide capsules and only 78 mg for the TPI 1020 capsules (equivalent to 25% less budesonide delivered to the lung in the TPI 1020 group). No other asthma medication, except rescue salbutamol, was permitted during the study.
Safety parameters
Safety parameters consisted of adverse events and serious adverse events, vital signs, asthma symptoms, laboratory determinations of complete blood counts (CBC), urinalysis, regular blood biochemistry, plasma C-reactive protein (CRP), plasma and urinary free cortisol levels, spirometry and electrocardiograms (ECGs). The asthma control scoring system questionnaire 11 (ACSS) was also used as a safety parameter. The ACSS questionnaire is made of three sections; a clinical score, the physiological score and the inflammation score. It was decided that for the physiological section of the questionnaire, the more informative FEV 1 would be preferred for assessment over the PEF or the diurnal fluctuation. The plasma pharmacokinetics (PK) profile of TPI 1020 and of budesonide was also determined on days 1 and 14 for up to 8 h after a dose in a sub-group of 8 to 10 patients per group.
Exploratory assessment of efficacy
Although this study was only powered to determine significant changes of the medication on neutrophils, the following parameters were also evaluated: sputum total cell and differential cell counts 12 on days 0, 15 and 22, predose FEV 1 measurements on days 0, 1, 14, 15 and 22, PEF measured with a Mini-Wright peak flow meter throughout the study, use of daily rescue medication (salbutamol) throughout the study, the response to methacholine challenge test 13 and the eNO levels (chemiluminescence after reaction with ozone) on days 0, 15 and 22 and plasma CRP levels on days 0, 15 and 22. Effects on FEV 1 over 8 h on days 1 and 14 were evaluated in a sub-group of 8 to 10 patients per group.
Determination of sample size
The sample size was chosen to provide information about safety, the primary study objective, and with the power to detect a 20% difference in the decrease in sputum neutrophils with TPI 1020 compared with budesonide. There were no published studies in mild smokers with asthma that had described the variability in sputum neutrophils. However, based on the publication by Gamble et al., 14 almost all patients with COPD had increased sputum neutrophils (>20%) and we then, by comparison with these data, calculated that if 13 subjects per group completed the study, a difference of 20% in neutrophils (%) between groups could be detected with a power of 80%.
Statistical analysis
The methods of analysis used to compare both treatment arms included Students t-test, Chi 2 test or Fisher exact test as appropriate for each variable. All tests of hypotheses were two-sided with statistical significance defined as p 0.05. Tests of normality were conducted for continuous variables, and as a result, the Wilcoxon rank sum test was used. Data are presented as mean AE standard error of the mean (SEM) unless otherwise noted. When data were not normally distributed, the results are presented as medians.
Results
Subject demographics
A total of 27 subjects were enrolled into the study: 13 in the TPI 1020 and 14 in the budesonide treatment group. One subject in the budesonide group withdrew, prior to receiving medication, resulting in 13 subjects in each group in the intent-to-treat population. Eight subjects in the TPI 1020 and 10 subjects in the budesonide group underwent PK and PD evaluations. All 26 subjects completed the study. Characteristics of the patients in the two groups were not significantly different, although FEV 1 , peak flow and sputum neutrophils tended to be lower, and eNO and sputum eosinophils tended to be higher in the TPI 1020-treated group (see Tables 1 and 2B ). There were also no differences between groups in hematology, chemistry, urine and ECG.
Safety
There was no serious adverse event during the study and only one severe adverse event (headache in a budesonidetreated patient). There was no difference in the number of subjects that reported adverse events between TPI 1020 (n Z 6) and budesonide (n Z 7). However, there were three-fold less total treatment-emergent adverse events in the TPI 1020-treated patients when compared to budesonide [13 versus 39 (see Fig. 1)] . The TPI 1020 AEs were: upper abdominal pain (2), headache (2), chest pain (1), muscle spasm (1), insomnia (1), ear discomfort (1), infective conjunctivitis (1), UTI (1), C-Reactive protein increased (1), dyspnea (1), excoriation (1), and lymphadenopathy (1). There were also less drug-related adverse events in TPI 1020-treated patients (6 versus 9).
Treatment with neither medication had any effect on standard parameters of hematology, chemistry and urine except for blood urea nitrogen (BUN). BUN increased significantly in the budesonide-treated group from 4. Both therapies also had no significant effects on morning plasma cortisol level (budesonide 13.1, 10.9 and 11.4 mcg/ dl and TPI 1020 13.7, 14.5 and 11.7 mcg/dl at baseline, days 15 and 22, respectively). However, budesonide significantly decreased 24 h urinary free cortisol whereas TPI 1020 had no such effect (see Fig. 2 ).
Effects on sputum neutrophils and other cells
A trend was found for a decrease in sputum neutrophils in the TPI 1020 group (see Fig. 3 ). Median sputum neutrophils changed from 39.6 to 41.1% in the budesonide group (3.7% increase) and from 29.8 to 20.1% in the TPI 1020 group (32.6% decrease). Since there was an unexpectedly large number of patients with normal baseline neutrophils in the sputum (9 of 26 patients with neutrophils <20%), a post hoc analysis was performed in patients with baseline sputum neutrophils >20% (abnormal) and those with sputum neutrophils <20% (normal). In those patients with high neutrophils at baseline, budesonide decreased sputum neutrophils from a mean of 55.1 to 51.9% over 22 days (5.8% decrease), TPI 1020 decreased sputum neutrophils from 50.8 to 33.4% over 22 days (35.8% decrease). Whilst in those patients with normal neutrophils at baseline, neither budesonide nor TPI 1020 decreased sputum neutrophils (changes were from a mean of 4.25 to 3.95% for budesonide and from 11.5 to 17.9% over 22 days for TPI 1020). In addition, for patients with high neutrophils at baseline, TPI 1020 decreased sputum neutrophils to <30% in most (57.1%) patients, whilst for none of the patients treated with budesonide were neutrophils decreased to <30%.
There were no differences for the effects of TPI 1020 versus budesonide on other cells (%) or total cells. Total cells went from 1.1 (1.0) at baseline to 1.2 (1.1) Â 10 6 cells on day 22 in budesonide-treated patients and from 0.7 (0.5) to 0.8 (0.5) Â 10 6 cells in TPI 1020-treated patients.
Exploratory assessment of efficacy
The effects of TPI 1020 and budesonide on airway function, symptoms and inflammatory parameters are presented in Tables 2A and 2B , respectively. There was no improvement in FEV 1 in both groups over the 3-week period. Morning PEF, rescue medication-free days, doses of rescue medication, PC 20 , and the ACSS score improved to a similar extent in the budesonide and the TPI 1020 groups. Sputum eosinophils, blood eosinophils and eNO tended to be higher at baseline in the TPI 1020 group but improved to the same extent as in the budesonide group. Blood lymphocytes increased in budesonide-treated patients, a difference that was significant when compared to TPI 1020-treated patients (p < 0.05). 
Pharmacodynamic activity
The effects of low dose TPI 1020 and budesonide on FEV 1 over an 8 h period on days 1 and 14 are presented in Fig. 4 . TPI 1020, at the lowest dose studied, had no acute effects on FEV 1 on both days when compared to budesonide.
Pharmacokinetic activity
TPI 1020 was not detected in the plasma of treated subjects at all time points assessed over an 8 h period on days 1 and 14, and on day 22, approximately 12 h after the last dose. The budesonide plasma phamacokinetic analysis was different in the TPI 1020 group when compared to the budesonide group Baseline and day 22 levels in budesonide and TPI 1020-treated patients. Change in % blood lymphocytes over time in budesonide-treated patients as compared to change in TPI 1020-treated patients, *p < 0.05, for all other comparisons the p were NS. SD, standard deviation; eNO, exhaled nitric oxide; CRP, C-reactive protein.
(see Fig. 5 ). The median values of Cmax (pg ml À1 ), Tmax (h) and AUC (pg mL 
Discussion
In this study we found that TPI 1020 is safe in patients with asthma and has similar effects as equivalent doses of budesonide on FEV 1 , PEF, PC 20 , use of rescue medication, eNO and eosinophilic inflammation. TPI 1020 had additional beneficial effects, possibly attributable to NO, on sputum neutrophils and plasma CRP, lower systemic budesonide exposure and lack of effect on 24 h urinary free cortisol. TPI 1020 may therefore be considered a potential drug candidate, not only for the treatment of allergic airway inflammation often associated with an eosinophil type of inflammation, but also for diseases where neutrophils and systemic inflammation can play a role.
Asthma is characterized by increased airway inflammation and elevated levels of exhaled NO. 2, 15, 16 Furthermore, when asthma becomes controlled with corticosteroid therapy, eNO often decreases to a level similar to that in normal individuals. 3 These results have led to speculation that NO is negatively influencing the ongoing inflammation within the airways of patients with asthma. However, NO has been shown to have additional beneficial effects, such as anti-viral and anti-bacterial properties, 17e19 and causes bronchodilation in patients with asthma. 5, 6 Over-expression of eNO is beneficial in a mouse model of allergic airway inflammation. 20 We assessed whether TPI 1020, a corticosteroid linked to an NO donor, would be safe in asthma. We chose smokers with asthma since this would also allow us to assess whether TPI 1020 would affect sputum neutrophils in these patients. All subjects were current smokers with a smoking history that was insufficient to induce clinically significant COPD.
TPI 1020 was safe in patients with asthma over the 3 weeks of administration, even at a dose that would be clinically equivalent to 1600 mcg of budesonide per day. With TPI 1020, we found a three-fold reduction in treatment-emergent adverse events and less adverse events that were considered by the investigator to be drugrelated, TPI 1020 may thus be advantageous over other inhaled corticosteroids at high doses. One of the measures that have been shown to help assess systemic absorption and potential long term toxicity of corticosteroids is the 24 h urinary free cortisol measurement 25 (UFC). A dose-response relationship between the dose of budesonide administered and UFC has been reported. 23 In this study we have confirmed that 1600 mcg of budesonide per day decreases UFC significantly. TPI 1020 had no significant effect on UFC at a dose of 2400 mcg per day. More studies are needed to understand the absorption, metabolism and distribution of TPI 1020 in humans, but the absence of effect of TPI 1020 on UFC may be related to the different plasma PK profile of budesonide in both treatment groups. Indeed, the Cmax and AUC of plasma budesonide were more than five-fold lower in the TPI 1020 group than in the corresponding budesonide group. It could thus be expected that less systemic exposure would translate to less effects on the adrenalepituitary axis.
Although this study was designed to assess safety, we did perform common measures associated with efficacy. This study was not powered for any of the standard measures of efficacy and results should be considered exploratory. In addition, the length of the study was not sufficient to determine the maximal effects of the corticosteroids. However, TPI 1020 seemed to have the same trends in effects on FEV 1 , PEF, days with rescue medication usage, the amount of rescue medication employed, asthma control score, methacholine response, sputum eosinophils and exhaled NO. It is interesting that TPI 1020 decreased eNO to a similar extent as the equimolar amount of budesonide (12.1 versus 9.2 ppb decrease with TPI 1020 versus budesonide, respectively). These results would suggest that the amount of NO released by TPI 1020 within the lungs is not sufficient to affect eNO or that the NO released is metabolized prior to its passage into the airways.
We also assessed whether TPI 1020, or the NO that it releases, would have additional pharmacological effects within the lungs. NO has been shown to inhibit neutrophil recruitment 4, 8 and TPI 1020 inhibited the recruitment of neutrophils into the lungs of a guinea pig model of LPSinduced lung inflammation, whilst budesonide was without effect in this model. 8 In our study, TPI 1020 decreased neutrophils in the sputum of patients with asthma after 22 days by 32.6%, whereas budesonide had no effect. Although we had powered the study for a 20% difference in sputum neutrophils between groups, the difference observed was not significant. We believe that this could be explained by the unexpectedly large number of patients with normal neutrophils at baseline in the TPI 1020-treated patients. Indeed, 6 of 13 TPI 1020-treated patients had sputum neutrophils at baseline below 20%. The finding that not all asthmatic smokers have increased neutrophils in their sputum is consistent with the results recently reported by Lazarus et al. 26 in mild asthmatic smokers. Interestingly, the decrease in sputum neutrophils caused by TPI 1020 occurred only in patients with high neutrophils at baseline suggesting that TPI 1020 is acting on the mechanism by which cigarette smoke recruits neutrophils into the airways, and not on the normal homeostatic mechanism of neutrophil recruitment.
Increased plasma CRP has been associated with increased mortality in patients with cardiovascular diseases and with COPD. 27 There is a controversy on whether inhaled corticosteroids decrease CRP in patients with COPD. 28 Although there was high variability in CRP results, TPI 1020 decreased CRP more than budesonide, a finding that would need to be reproduced in larger studies. These effects may be caused by the additional anti-inflammatory effects of NO on chemokines and cytokines.
Conclusions
This study showed that TPI 1020 was safe in patients with asthma. In addition to having similar efficacy effects as budesonide on asthma, TPI 1020 had an improved PK profile with no effects on UFC, and additional effects on sputum neutrophils and plasma CRP. These observations suggest that this new agent may be considered as a novel therapeutic option for airways diseases where increased neutrophils and systemic inflammation play a role.
